Chapter 35 (4) Flashcards
Type 2 diabetes is a complex disorder involving:
A suboptimal response of insulin-sensitive tissues in the liver
Type 1 diabetes results from autoimmune destruction of the beta cells. Eighty-five to 90% of type 1 diabetics have:
Autoantibodies to two tyrosine phosphatases
Diagnostic criteria for diabetes include:
Symptoms of diabetes plus a casual blood glucose greater than 200 mg/dl
Routine screening of asymptomatic adults for diabetes is appropriate for:
Native Americans, African Americans, and Hispanics
Screening for children who meet the following criteria should begin at age 10 and occur every 3 years thereafter:
Any of the above
Insulin is used to treat both types of diabetes. It acts by:
Increasing peripheral glucose uptake by skeletal muscle and fat
Adam has type 1 diabetes and plays tennis for his university. He exhibits a knowledge deficit about his insulin and his diagnosis. He should be taught that:
He should increase his carbohydrate intake during times of exercise.
Insulin preparations are divided into categories based on onset, duration, and intensity of action following subcutaneous injection. Which of the following insulin preparations has the shortest onset
and duration of action?
Glulisine
The drug of choice for type 2 diabetics is metformin. Metformin:
Decreases glycogenolysis by the liver
Before prescribing metformin, the provider should:
Draw a serum creatinine level to assess renal function.
Sulfonylureas may be added to a treatment regimen for type 2 diabetics when lifestyle modifications and metformin are insufficient to achieve target glucose levels. Sulfonylureas have been moved to
Step 2 therapy because they:
Have a significant risk for hypoglycemia
Dipeptidyl peptidase-4 inhibitors (gliptins) act on the incretin system to improve glycemic control. Advantages of these drugs include:
Low risk for hypoglycemia
Control targets for patients with diabetes include:
Blood pressure less than 130/80 mm Hg
Establishing glycemic targets is the first step in treatment of both types of diabetes. For type 1 diabetes:
Conventional therapy has a fasting plasma glucose target between 120 and 150 mg/dl.
Treatment with insulin for type 1 diabetics:
Starts with a total daily dose of 0.2 to 0.4 units per kg of body weight